Effectiveness of pulmonary vasodilators on pulmonary hypertension associated with POEMS syndrome.
Kana OhashiRintaro NishimuraShunsuke SugimotoSeiichiro SakaoNobuhiro TanabeKoichiro TatsumiPublished in: Respirology case reports (2019)
Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome is a rare plasma cell disease. Patients with POEMS syndrome are considered to be at a high risk of developing pulmonary hypertension (PH). We report a 51-year-old woman diagnosed with PH associated with POEMS syndrome. She was started on dexamethasone and thalidomide. Although, the plasma vascular endothelial growth factor (VEGF) level decreased, systolic pulmonary artery pressure (sPAP) remained high. Auto-peripheral blood stem cell transplantation improved the plasma VEGF and sPAP levels. Four years later, she presented with dyspnoea on exertion, and elevated plasma VEGF and sPAP levels. Subsequently, on administering sildenafil and macitentan, the plasma VEGF and PH levels improved. Pulmonary vasodilators can be considered when PH remains after treatment of POEMS syndrome.
Keyphrases
- pulmonary hypertension
- vascular endothelial growth factor
- pulmonary artery
- pulmonary arterial hypertension
- stem cell transplantation
- endothelial cells
- case report
- peripheral blood
- coronary artery
- high dose
- randomized controlled trial
- systematic review
- blood pressure
- heart failure
- low dose
- bone marrow
- left ventricular
- mesenchymal stem cells